915754-05-1

Basic information

• Product Name: N-[2-(3,4-DiMethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonaMide
• Synonyms: BML-287;N-[2-(3,4-DiMethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonaMide
• CAS NO: 915754-05-1
• Molecular Formula: C24H27NO6S2
• Molecular Weight: 489.60428
• Product Categories: Aromatics;Inhibitor;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 915754-05-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[2-(3,4-DiMethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(3,4-DiMethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonaMide(915754-05-1)
• EPA Substance Registry System: N-[2-(3,4-DiMethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonaMide(915754-05-1)

Safety Data

• Hazardous Substances Data: 915754-05-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
BML-287 is used as a research tool for studying the Wnt signaling pathway, which is involved in various cellular processes, including cell proliferation, differentiation, and migration. Understanding the role of sFRP-1 in this pathway can help in the development of targeted therapies for various diseases.
Used in Drug Development:
BML-287 is used as a lead compound in the development of new drugs targeting the Wnt signaling pathway. Its selective inhibition of sFRP-1 makes it a promising candidate for the treatment of diseases where the Wnt pathway is dysregulated, such as cancer and neurodegenerative disorders.
Used in Cancer Research:
In cancer research, BML-287 is used as a potential therapeutic agent for the treatment of various types of cancer. The Wnt signaling pathway is often implicated in the development and progression of cancer, and targeting sFRP-1 with BML-287 may help in inhibiting tumor growth and metastasis.
Used in Neurodegenerative Disease Research:
BML-287 is also used in the study of neurodegenerative diseases, where the Wnt signaling pathway has been implicated in the pathogenesis of conditions such as Alzheimer's and Parkinson's disease. By targeting sFRP-1, BML-287 may help in understanding the role of the Wnt pathway in these diseases and potentially lead to the development of novel therapeutic strategies.

Upstream product

• 1093989-15-1 5-benzenesulfonyl-2-ethylbenzenesulfonyl chloride 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 

Relevant articles and documents

Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors

Inhibitor of secreted frizzled related protein-1 (sFRP-1) would be a novel potential osteogenic agent, since loss of sFRP-1 affects osteoblast proliferation, differentiation, and activity, resulting in improved bone mineral density, quality, and strength. We have identified small molecule diarylsulfone sulfonamide derivatives as sFRP-1 inhibitors. Structure-activity relationship generated for various regions of the scaffold was utilized to improve the biochemical profile, resulting in the identification of potent selective analogues, such as 16 with desirable pharmaceutical profile.

DIARYLSULFONE SULFONAMIDES AND USE THEROF

Compounds of Formula (I), or pharmaceutically acceptable salts thereof, are provided, which are modulators of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis.